Hitachi Healthcare Americas Corp. and MD Anderson Cancer Center announced an agreement to collaborate on a randomized clinical trial comparing the outcomes and side-effects of intensity-modulated proton beam therapy versus intensity-modulated photon therapy for the treatment of oropharyngeal cancer of the head and neck.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
